Cholecystokinin, vasoactive intestinal peptide and peptide histidine methionine responses to feeding in anorexia nervosa.
Anorexia nervosa (AN) is a syndrome of unknown cause characterized by voluntary starvation. Cholecystokinin has been implicated as a neuroendocrine regulatory factor in control of satiety. Relatively little information is known about gastrointestinal hormone responses to feeding in subjects with anorexia nervosa. In the present studies, we examine fasting and postprandial levels of cholecystokinin (CCK), vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) in anorexia nervosa subjects and in control individuals. Results of these studies indicate that plasma CCK response to a liquid meal (Ensure Plus) in untreated AN subjects was distinctly different from that observed in healthy controls, both in terms of temporal pattern of peptide released and the amount of CCK secreted into the circulation. Peak levels of CCK release occurred at 30 min following meal ingestion in AN patients and at 60 min in control subjects. Integrated CCK release in untreated AN patients was approximately twice that measured in control individuals. Renutrition therapy was associated with reversion of the pattern of CCK release to that observed in control subjects. Plasma VIP levels were unchanged following meal ingestion in both control and anorexic subjects. In contrast, PHM levels in AN subjects were significantly greater than that observed in control individuals. The pattern of PHM release following liquid meal ingestion was similar to that observed with plasma CCK; namely, peak release of peptide was observed at 30 min which was significantly greater than corresponding control values (P less than 0.05). In conclusion, these results demonstrate distinctive differences in plasma CCK and PHM levels in response to feeding in AN subjects when compared to control individuals. These findings suggest that the earlier and greater rise in plasma CCK levels in AN subjects following meal ingestion may contribute to the abnormal sensation of satiety in this condition.
Harty
R F
RF
Department of Internal Medicine, University of Nebraska Medical Center, Omaha.
Pearson
P H
PH
Solomon
T E
TE
McGuigan
J E
JE
D000856:Anorexia Nervosa / Q000209:etiology* / Q000628:therapy; D002766:Cholecystokinin / Q000378:metabolism; D004035:Diet Therapy; D004435:Eating / Q000502:physiology*; D005260:Female; D005526:Food, Formulated; D005768:Gastrointestinal Hormones / Q000378:metabolism*; D006801:Humans; D010451:Peptide PHI / Q000378:metabolism*; D010949:Plasma / Q000737:chemistry; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism
D005768:Gastrointestinal Hormones; D010451:Peptide PHI; D014660:Vasoactive Intestinal Peptide; D002766:Cholecystokinin